The approval of the cystic fibrosis transmembrane conductance regulator (CFTR) modulator triple therapy elexacaftor/tezacaftor/ivacaftor (ETI) in 2019 was a breakthrough in the treatment of people with cystic fibrosis (pwCF). This evidence concerns the gene CFTR and cystic fibrosis.